糖脂代谢紊乱是威胁人类健康和生命的主要因素。遗传,环境,心理,细胞,和分子因素有助于其发病机制。一些研究表明,神经内分泌轴功能障碍,胰岛素抵抗,氧化应激,慢性炎症反应,肠道菌群失调是与其相关的核心病理联系。然而,糖脂代谢紊乱的潜在分子机制和治疗靶点仍有待阐明。高通量技术的进展有助于阐明糖脂代谢紊乱的病理生理学。在本次审查中,我们探索了基因组学的方法和方法,转录组学,蛋白质组学,代谢组学,和肠道微生物可以帮助识别新的候选生物标志物,用于糖脂代谢紊乱的临床管理。我们还讨论了这些疾病的多组学研究的局限性和建议的未来研究方向。
Glycolipid metabolism disorder are major threats to human health and life. Genetic, environmental, psychological, cellular, and molecular factors contribute to their pathogenesis. Several studies demonstrated that neuroendocrine axis dysfunction, insulin resistance, oxidative stress, chronic inflammatory response, and gut microbiota dysbiosis are core pathological links associated with it. However, the underlying molecular mechanisms and therapeutic targets of glycolipid metabolism disorder remain to be elucidated. Progress in high-throughput technologies has helped clarify the pathophysiology of glycolipid metabolism disorder. In the present review, we explored the ways and means by which genomics, transcriptomics, proteomics, metabolomics, and gut microbiomics could help identify novel candidate biomarkers for the clinical management of glycolipid metabolism disorder. We also discuss the limitations and recommended future research directions of multi-omics studies on these diseases.